BioStem Technologies (OTCMKTS:BSEM – Get Free Report) and Legend Biotech (NASDAQ:LEGN – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.
Volatility & Risk
BioStem Technologies has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.
Valuation and Earnings
This table compares BioStem Technologies and Legend Biotech”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioStem Technologies | $47.48 million | 1.24 | -$19.79 million | ($1.11) | -2.99 |
| Legend Biotech | $1.14 billion | 3.03 | -$296.80 million | ($0.68) | -27.28 |
BioStem Technologies has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than BioStem Technologies, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for BioStem Technologies and Legend Biotech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioStem Technologies | 0 | 1 | 0 | 1 | 3.00 |
| Legend Biotech | 1 | 5 | 9 | 0 | 2.53 |
BioStem Technologies presently has a consensus price target of $9.00, suggesting a potential upside of 171.56%. Legend Biotech has a consensus price target of $55.29, suggesting a potential upside of 198.04%. Given Legend Biotech’s higher possible upside, analysts clearly believe Legend Biotech is more favorable than BioStem Technologies.
Institutional and Insider Ownership
70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares BioStem Technologies and Legend Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioStem Technologies | N/A | N/A | N/A |
| Legend Biotech | -21.98% | -24.92% | -14.87% |
Summary
Legend Biotech beats BioStem Technologies on 8 of the 15 factors compared between the two stocks.
About BioStem Technologies
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Receive News & Ratings for BioStem Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioStem Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
